418 related articles for article (PubMed ID: 30579984)
21. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
Kordower JH
Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
[TBL] [Abstract][Full Text] [Related]
22. Potential applications of nanotechnologies to Parkinson's disease therapy.
Linazasoro G;
Parkinsonism Relat Disord; 2008; 14(5):383-92. PubMed ID: 18329315
[TBL] [Abstract][Full Text] [Related]
23. [Future drug targets for Parkinson's disease].
Hirsch EC
Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
[TBL] [Abstract][Full Text] [Related]
24. Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease.
Yang PH; Zhu JX; Huang YD; Zhang XY; Lei P; Bush AI; Xiang Q; Su ZJ; Zhang QH
Neurodegener Dis; 2016; 16(5-6):357-69. PubMed ID: 27228974
[TBL] [Abstract][Full Text] [Related]
25. Exosomes as drug delivery vehicles for Parkinson's disease therapy.
Haney MJ; Klyachko NL; Zhao Y; Gupta R; Plotnikova EG; He Z; Patel T; Piroyan A; Sokolsky M; Kabanov AV; Batrakova EV
J Control Release; 2015 Jun; 207():18-30. PubMed ID: 25836593
[TBL] [Abstract][Full Text] [Related]
26. Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease.
Lafuente JV; Requejo C; Carrasco A; Bengoetxea H
Int Rev Neurobiol; 2017; 137():99-122. PubMed ID: 29132545
[TBL] [Abstract][Full Text] [Related]
27. Disease-modifying drugs and Parkinson's disease.
Allain H; Bentué-Ferrer D; Akwa Y
Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
[TBL] [Abstract][Full Text] [Related]
28. Nanotechnology As Potential Tool for siRNA Delivery in Parkinson's Disease.
Cortes H; Alcala-Alcala S; Avalos-Fuentes A; Mendoza-Munoz N; Quintanar-Guerrero D; Leyva-Gomez G; Floran B
Curr Drug Targets; 2017 Nov; 18(16):1866-1879. PubMed ID: 28325145
[TBL] [Abstract][Full Text] [Related]
29. Parkinson's Disease, Diabetes and Cognitive Impairment.
Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
[TBL] [Abstract][Full Text] [Related]
30. Nanomedicine based nanoparticles for neurological disorders.
Sriramoju B; Kanwar RK; Kanwar JR
Curr Med Chem; 2014; 21(36):4154-68. PubMed ID: 25039778
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicine against Alzheimer's and Parkinson's Disease.
Tandon A; Singh SJ; Chaturvedi RK
Curr Pharm Des; 2021; 27(12):1507-1545. PubMed ID: 33087025
[TBL] [Abstract][Full Text] [Related]
32. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.
Shadfar S; Kim YG; Katila N; Neupane S; Ojha U; Bhurtel S; Srivastav S; Jeong GS; Park PH; Hong JT; Choi DY
Mol Neurobiol; 2018 Jan; 55(1):554-566. PubMed ID: 27975170
[TBL] [Abstract][Full Text] [Related]
34. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.
Aly AE; Waszczak BL
Expert Opin Drug Deliv; 2015; 12(12):1923-41. PubMed ID: 26289676
[TBL] [Abstract][Full Text] [Related]
35. Recent progress of drug nanoformulations targeting to brain.
Khan AR; Yang X; Fu M; Zhai G
J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective strategies in Parkinson's disease : an update on progress.
Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
Sarkar S; Raymick J; Imam S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
[TBL] [Abstract][Full Text] [Related]
38. Oral Delivery of Puerarin Nanocrystals To Improve Brain Accumulation and Anti-Parkinsonian Efficacy.
Xiong S; Liu W; Li D; Chen X; Liu F; Yuan D; Pan H; Wang Q; Fang S; Chen T
Mol Pharm; 2019 Apr; 16(4):1444-1455. PubMed ID: 30811206
[TBL] [Abstract][Full Text] [Related]
39. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.
O'Neill MJ; Messenger MJ; Lakics V; Murray TK; Karran EH; Szekeres PG; Nisenbaum ES; Merchant KM
Int Rev Neurobiol; 2007; 77():179-217. PubMed ID: 17178475
[No Abstract] [Full Text] [Related]
40. Neurotrophic factors and neurodegenerative diseases: a delivery issue.
Ruozi B; Belletti D; Bondioli L; De Vita A; Forni F; Vandelli MA; Tosi G
Int Rev Neurobiol; 2012; 102():207-47. PubMed ID: 22748832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
